杨丽霞, 苗贵华, 齐峰, 王先梅, 石燕昆, 任丽, 李明秋. 冠心病患者激活蛋白-1和脂联素与冠状动脉病变的关系[J]. 心脏杂志, 2009, 21(5): 669-671.
    引用本文: 杨丽霞, 苗贵华, 齐峰, 王先梅, 石燕昆, 任丽, 李明秋. 冠心病患者激活蛋白-1和脂联素与冠状动脉病变的关系[J]. 心脏杂志, 2009, 21(5): 669-671.
    Relationship of activator protein-1 and adiponectin and coronary atherosclerosis in patients with coronary heart disease[J]. Chinese Heart Journal, 2009, 21(5): 669-671.
    Citation: Relationship of activator protein-1 and adiponectin and coronary atherosclerosis in patients with coronary heart disease[J]. Chinese Heart Journal, 2009, 21(5): 669-671.

    冠心病患者激活蛋白-1和脂联素与冠状动脉病变的关系

    Relationship of activator protein-1 and adiponectin and coronary atherosclerosis in patients with coronary heart disease

    • 摘要: 目的: 探讨冠心病(CHD)患者外周血白细胞内激活蛋白-1(AP-1)和血浆脂联素浓度与CHD及冠状动脉粥样硬化病变的关系。方法: 冠状动脉造影患者142例,分为CHD组和对照组。CHD组根据临床类型分为稳定型心绞痛(SAP)和急性冠脉综合征(ACS)组;根据冠状动脉病变类型分为A,B和C型病变组;根据冠状动脉病变狭窄程度分为轻、中和重度病变组。用ELISA法测定外周血白细胞裂解液中磷酸化c-Jun吸光度(A),反映活化AP-1数量;血浆脂联素浓度通过ELISA法测定。结果: CHD组磷酸化c-Jun明显高于对照组(1.43±0.33 vs 0.71±0.13, P<0.01),脂联素明显低于对照组[(6.1±1.8) mg/L vs (10.2±1.5) mg/L, P<0.01];ACS组磷酸化c-Jun明显高于SAP组(1.56±0.28 vs 1.14±0.25, P<0.01) ,脂联素明显低于SAP组[(5.4±1.5) mg/L vs (7.6±1.7) mg/L, P<0.01]。随冠状动脉病变类型和病变程度的加重,磷酸化c-Jun逐渐升高,脂联素逐渐降低。脂联素浓度与冠脉Gensini评分呈负相关(P<0.05)。结论: 磷酸化c-Jun表达量增高和血浆脂联素浓度降低与CHD类型及冠脉病变情况显著相关。

       

      Abstract: AIM: To investigate the relation between plasma adiponectin concentration and activator protein-1 (AP-1) in peripheral blood and coronary heart disease (CHD) and coronary arteriosclerosis changes in patients with CHD. METHODS: One hundred and forty-two patients were divided into CHD group and control group according to the outcome of coronary angiography (CAG). CHD group was further divided into stable angina pectoris (SAP) group and acute coronary syndrome (ACS) group according to clinical diagnosis. According to the type of coronary changes, CHD group was divided into type A, type B and type C groups and according to the degree of coronary lesion, CHD group was further divided into light stenosis group, moderate stenosis group and severe stenosis group. Phospho-c-Jun in lysate and plasma adiponectin concentrations were measured by enzyme-linked immunosorbent assay (ELISA). RESULTS: Absorbance of Phospho-c-Jun in the CHD group was significantly higher than in control subjects (1.43±0.33 vs.0.71±0.13, P<0.01). Plasma adiponectin concentration in the CHD group was significantly lower than in control subjects [(6.1±1.8)mg/L vs.(10.2±1.5)mg/L, P<0.01]. Absorbance of Phospho-c-Jun in ACS group was significantly higher than in the SAP group (1.56±0.28 vs.1.14±0.25, P<0.01). Plasma adiponectin concentration in the ACS group was significantly lower than in the SAP group [(5.4±1.5)mg/L vs.(7.6±1.7)mg/L, P<0.01]. Absorbance of Phospho-c-Jun increased gradually from type A group to type C group and from light stenosis group to severe stenosis group. Plasma adiponectin concentration decreased gradually from type A group to type C group and from light stenosis group to severe stenosis group. CONCLUSION: Increase of Phospho-c-Jun (AP-1) and decrease of adiponectin are significantly related to CHD and coronary atherosclerosis changes.

       

    /

    返回文章
    返回